Wall Street strategists are advising a shift away from the dominant technology giants, suggesting investors buy into less popular sectors like health care, industrials, and energy for 2026. Concerns over Big Tech’s lofty valuations and AI spending, amplified by recent earnings reports, are driving this rotation.
Wockhardt shares rocket 19% after FDA approval for antibiotic targeting drug-resistant infections. Check details
Wockhardt’s shares surged 19% after the U.S. FDA approved ZAYNICH, a novel intravenous antibiotic for complicated urinary tract infections. The drug, combining cefepime and zidebactam,